Explore

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

The U.S. Department of Health and Human Services (HHS) has announced a new program and three complementary projects aimed at significantly speeding up clinical trials through the integration of artificial intelligence (AI), advanced computational models, and real-time analysis. The core initiative, named SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), seeks to develop AI-powered platforms that will continuously and adaptively support clinical trial designs. This program includes the creation of a phaseless design engine to simulate trials for faster results with fewer patients, a continuous inference engine for real-time data analysis and trial adaptations, and an agentic AI operations layer to automate startup activities and data collection. These efforts are part of a broader strategy by HHS to transform U.S. clinical trials, building on previous initiatives like Operation TrialBlazer and the FDA's pilot program using AI for real-time clinical trial data monitoring. The goal ...

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

AstraZeneca and Daiichi Sankyo Collaborate on Clinical Trials for Datopotamab Deruxtecan in Cancer Treatment

Illumina Seeks Oncology Medical Science Liaison to Advance Precision Medicine Research

Illumina Seeks Oncology Medical Science Liaison to Advance Precision Medicine Research

Illumina, a global leader in DNA and multi-omic sequencing, is actively seeking a Sr. Staff Medical Science Liaison (MSL) in Oncology. This role is crucial for advancing precision medicine research, particularly in the field of oncology. The selected individual will be responsible for demonstrating a comprehensive understanding of Illumina's product offerings, recent medical and scientific advancements, and key publications related to precision medicine in oncology. A core aspect of the position involves fostering and maintaining collaborative relationships with external scientific leaders and stakeholders. This engagement aims to facilitate scientific exchange, gather insights, and understand the evolving scientific, clinical, and research needs within the genomics community. The MSL will also manage relationships with healthcare professionals (HCPs), healthcare organizations (HCOs), professional societies, and customers across the U.S. to support scientific education and communication regarding genomic t...

New Molecular Matching Approach Shows Promise for Longer Survival in Advanced Cancer Patients

New Molecular Matching Approach Shows Promise for Longer Survival in Advanced Cancer Patients

A study published in npj Genomic Medicine introduces a new computational approach, the Molecular Therapy Matching Score, designed to improve precision oncology by considering the entire molecular profile of a patient's tumor rather than focusing on single genomic alterations. This method integrates various genomic alterations and molecular information to assess how effectively a drug or combination therapy addresses the tumor's overall characteristics. A retrospective analysis of 540 patients with advanced or metastatic cancer, including common types like breast and colorectal cancer, revealed that higher Molecular Therapy Matching Scores were significantly associated with longer progression-free and overall survival. For instance, patients with 67–100% matching had a median progression-free survival of 9.0 months compared to 3.0 months for those with 0% matching. Similarly, median overall survival was 18.7 months versus 9.0 months, respectively. The study was primarily funded by CureMatch, the company beh...

Eli Lilly's Jaypirca Approved for First-Line Treatment of CLL/SLL in U.S.

Eli Lilly's Jaypirca Approved for First-Line Treatment of CLL/SLL in U.S.

Eli Lilly's Jaypirca Approved for First-Line Treatment of CLL/SLL in U.S.

Celaid Therapeutics Secures Additional Funding for U.S. Clinical Trials of CLD-001

Celaid Therapeutics Secures Additional Funding for U.S. Clinical Trials of CLD-001

Celaid Therapeutics Inc., a biotechnology startup, has completed the second close of its Series B financing round, raising an additional JPY 400 million (approximately USD 2.6 million). New investors, including Shionogi & Co., Ltd. and Teikoku Ventures, Inc., joined this round. This funding, combined with support from AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem,' brings Celaid's total cumulative funding to approximately JPY 3.42 billion (approximately USD 22.1 million). The proceeds are primarily earmarked for manufacturing, safety assessment, clinical development, and regulatory activities to support the Investigational New Drug (IND) application and the initiation of clinical trials in the United States for CLD-001. CLD-001 is a novel ex vivo-expanded hematopoietic stem cell (HSC) therapy product designed for severe pediatric non-malignant diseases.

CRISPR Gene Therapies Advance Towards Direct In-Body Genome Editing for Inherited Retinal Disease

CRISPR Gene Therapies Advance Towards Direct In-Body Genome Editing for Inherited Retinal Disease

CRISPR gene editing therapies are progressing from ex vivo (outside the body) modifications to direct in-vivo (inside the body) genome editing. A significant development in this area is the BRILLIANCE clinical trial, which in 2020 treated its first patient with EDIT-101, an experimental CRISPR/Cas9 therapy for Leber congenital amaurosis type 10 (LCA10). LCA10 is a rare inherited retinal disorder caused by mutations in the CEP290 gene. The treatment involves a subretinal injection designed to deliver the editing machinery directly to retinal cells. The eye is considered an ideal environment for such research due to its contained tissue, allowing for localized treatment delivery. While this represents a major step forward, researchers emphasize that these results should not be mistaken for an established human clinical therapy. The field is also exploring in-vivo approaches for other tissues, such as the liver, using lipid nanoparticles for systemic administration, with some experimental programs already in ...

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

Enable Biosciences Advances Early Type 1 Diabetes Detection with Predictive Tools

Enable Biosciences Advances Early Type 1 Diabetes Detection with Predictive Tools

Enable Biosciences, a San Francisco-based biotechnology company, has developed predictive medicine tools to identify individuals eligible for preventative therapy for type 1 diabetes (T1D). These tools utilize advanced antibody testing to detect autoantibody biomarkers that appear years before clinical symptoms of T1D manifest. According to Peter Robinson, Co-Founder and Chief Operating Officer of Enable Biosciences, their test is highly effective at predicting who will develop T1D. This early detection is crucial because a drug therapy, approved in November 2022, can delay the onset of T1D, but it must be administered before clinical symptoms or metabolic indications appear. The company's Antibody Detection by Agglutination-PCR (ADAP) technology screens for three major T1D-associated autoantibodies: GAD65, IA-2, and Insulin autoantibodies. While the test is a laboratory-developed test and has not been cleared or approved by the U.S. Food and Drug Administration (FDA), it is offered through a CLIA-certifie...

Precision Medicine Platform Targets Acute Myeloid Leukemia with Personalized Therapies

Precision Medicine Platform Targets Acute Myeloid Leukemia with Personalized Therapies

A new research project, funded by IFAB and coordinated by Professor Giovanni Roti of the University of Parma, is developing a functional precision medicine platform to treat acute myeloid leukemia (AML). This initiative aims to move beyond conventional, often ineffective, treatments for AML, particularly in elderly patients. The project focuses on the individual variability of the disease, recognizing that cancer manifests differently in each patient. Researchers are utilizing advanced algorithms to test hundreds of non-commercialized pharmacological molecules on individual cancer cells. This approach significantly expands the scope of drug testing compared to the standard pool of about 15 drugs currently used for AML. The ultimate goal is to identify personalized therapeutic profiles that are more effective and can treat a larger percentage of patients who are currently considered untreatable. The project seeks to shift the paradigm from a one-size-fits-all treatment to therapies tailored to specific dise...

Orano Med Expands Lead-212 Production with New U.S. Facility for Cancer Therapies

Orano Med Expands Lead-212 Production with New U.S. Facility for Cancer Therapies

Orano Med, a clinical-stage biotechnology company and subsidiary of the Orano group, is expanding its global manufacturing capabilities for lead-212-based targeted alpha therapies (TATs) for cancer treatment. Following the inauguration of its ATLab Valenciennes in France, which is Europe's first industrial-scale pharmaceutical facility dedicated to producing these radioligand therapies, Orano Med is also commissioning a similar production site in Indianapolis, in the U.S. This U.S. facility is designed to serve the North American market, mirroring the European site's goal of large-scale production to meet patient needs. The company's TATs utilize lead-212 (212Pb), an alpha-emitting radioisotope, as a potent therapeutic payload against cancer cells. Orano Med's strategy involves developing several 212Pb-based radioligand therapies combined with various targeting agents, with four drug candidates currently in clinical development and a broad preclinical pipeline. The logistical demands for these treatments a...

Fenbendazole Not Approved for Human Cancer Treatment, Poses Risks

Fenbendazole Not Approved for Human Cancer Treatment, Poses Risks

Fenbendazole, an antiparasitic medicine used in veterinary medicine to treat certain worm infections in animals, is not approved for human use in the United States, particularly for cancer treatment. Despite online discussions and personal testimonials suggesting its efficacy against cancer, there is no reliable clinical evidence to support these claims. The drug works by interfering with microtubules in parasites, which are also present in cancer cells, leading to scientific interest. However, laboratory findings and animal studies do not translate directly to safe and effective human treatments. The U.S. Food and Drug Administration has not approved fenbendazole for any human use, and there is no established, clinically validated dosing regimen for human cancer. Individuals considering or currently using fenbendazole for cancer are strongly advised to consult their oncology team to discuss potential risks and available evidence-based treatments.